A potential extracellular target for inositol phosphates and analogues with anticancer properties is identified. Proteins from detergent-solubilised HeLa cell lysates bound to a novel affinity column of myo-inositol 1,3,4,5,6-pentakisphosphate (InsP 5 coupled to Affigel-10. One high-affinity ligand was fibrinogen B . Inositol phosphates and analogues were able to elute purified fibrinogen from this matrix. InsP 5 and the inositol phosphate mimic biphenyl 2,3 ,4,5 ,6-pentakisphosphate (BiPhP 5 bound fibrinogen in vitro, and blocked the effects of fibrinogen in A549 cell-based assays of proliferation and migration. They were also able to prevent the fibrinogen-mediated activation of phosphatidylinositol 3-kinase. These effects of fibrinogen appeared to be mediated through the intercellular adhesion molecule-1 (ICAM-1), as cells not expressing ICAM-1 failed to respond. In contrast, myo-inositol hexakisphosphate and the epimeric scyllo-inositol 1,2,3,4,5-pentakisphosphate were without effect. These findings are consistent with earlier reports that higher inositol phosphates have anticancer properties. This new mechanism of action and target for these extracellular inositol phosphates to have their effects allows a re-evaluation of earlier data.
INTRODUCTION
Inositol-containing compounds are known to play critical roles as intracellular second messengers. Phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P 2 is the precursor to two key inositol-containing messengers; myo-Inositol 1,4,5-trisphosphate (Ins(1,4,5)P 3 is a water-soluble messenger that acts on its receptors in the endoplasmic reticulum causing calcium mobilisation from intracellular stores [Streb et al., 1983] , whereas the product of phosphoinositide 3-kinase (PI 3-K), PtdInsP 3 remains in the membrane and acts to recruit many proteins involved in proliferation, cancer, inflammation and diabetes [Vanhaesebroeck et al., 2001] .
Whilst the intracellular role of particular inositol phosphates has been established, much controversy surrounds their extracellular effects. In vitro assays have shown that the addition of high concentrations (5 mM) of myo-inositol hexakisphosphate (InsP 6 (Fig. 1) inhibits proliferation of cancer cell lines [El-Sherbiny et al., 2001 ]. These findings have been supported in animal models in which InsP 6 provides a protective effect against many cancers [Vucenik et al., 1997] . More recently, it has been shown that these effects can be mimicked by other inositol phosphates, particularly myo-inositol 1,3,4,5,6-pentakisphosphate (InsP 5 (Fig. 1 ), which appears more effective in decreasing growth rate, metastasis formation and preventing tumour development than InsP 6 [Maffucci et al., 2005; Piccolo et al., 2004] requiring doses of 50 M in vitro and 50 mg/kg in vivo. These extracellular effects are nonphysiological as InsP 5 and InsP 6 levels are normally very low [Letcher et al., 2008] unless a high InsP 6 diet is maintained [Grases et al., 2001] . Intracellular targets for inositol phosphates have been identified, including proteins downstream of PI 3-K [Downes et al., 2005; Komander et al., 2004] , and inhibiting these proteins would, indeed, cause a decrease in proliferation. Whether extracellular inositol phosphates can access these proteins has not been determined. Alternative mechanisms as to how these molecules work include binding extracellular proteins or cell-surface receptors. We have, therefore, searched for novel proteins that bind inositol phosphates in order to explain these effects using a novel affinity matrix. Our studies show that inositol phosphates bind TO fibrinogen and act to antagonise fibrinogen's ability to activate PI 3-K and cause proliferation and migration.
Whilst many intracellular targets of InsP 5 have been identified, the extracellular targets for InsP 5 remain elusive. The ability of inositol phosphates to bind and chelate fibrinogen could explain their antiproliferative and antimetastatic effects. A similar approach, targeting vascular endothelial growth factor (VEGF) with soluble decoy receptors (aflibercept -or VEGF Trap, Regeneron/SanofiAventis) [Holash et al., 2002] is in phase III clinical trials for the treatment of lung and prostate cancer. The VEGF antibody bevacizumab (Avastin, Genentech/Roche) has already been given FDA approval.
MATERIALS AND METHODS

Materials
InsP 5 , scyllo-inositol 1,2,3,4,5-pentakisphosphate (scylloInsP 5 and biphenyl 2,3 ,4,5 ,6-pentakisphosphate (BiPhP 5 were prepared as previously reported [Riley et al., 2006; Vandeput et al., 2007] . All compounds were purified to homogeneity by ion-exchange chromatography. The InsP 5 matrix was prepared by conjugation of 2-O-(2-aminoethyl)-InsP 5 with Affigel-10 (Bio-Rad UK) using methods previously reported for the corresponding InsP 3 resin . See Figure 1 for relevant structures.
Preparation of HeLa Cell Extracts, Binding, Elution and Identification
Whole HeLa cells were purchased from CilBiotech (Mons, Belgium) and solubilised in a buffer consisting of TrisHCl, 50 mM pH 7.5; NaCl 150 mM; Nonidet P40 1%; glycerol 10%; sodium orthovanadate 1 mM; ethylenediaminetetraacetic acid 5 mM; -glycerophosphate 5 mM; NaF 10 mM. Remaining particulate matter was removed by centrifugation, and the supernatant loaded onto the InsP 5 matrix. Following a rigorous wash with buffer containing 1M NaCl, proteins were eluted with a gradient of InsP 6 . The capacity of the resin was approximately 40 g protein/packed ml resin. SDS-PAGE of fractions identified fractions containing protein. Proteins with the highest affinity for the matrix (requiring 1 mM InsP 6 to elute were precipitated with HClO 4 (0.6 M), washed and sent for analysis at the Fingerprints Proteomics Facility, College of Life Sciences, University of Dundee.
Analysis of tryptic digests identified one major protein bound to the InsP 5 matrix. Two peptides were identified as EGVNDNEEGFFSAR and RARPAKA. Mascot analysis determined these peptides as originating from fibrinogen B .
Confirmation of Binding
Human fibrinogen (F4883, Sigma) was dissolved in 50 mM Tris, pH 7.4. 100 l of 10 mg/ml was loaded onto InsP 5 matrix and washed with 3 × 5 ml buffer. Protein was eluted with 1 ml aliquots of 1 nM-1 mM inositol phosphate or analogue. Finally the column was washed with 2 × 1 ml 10 mM InsP 6 . Protein concentration was determined from each fraction using Coomassie blue reagent.
Cell-Based Assays
A549 human lung carcinoma cells (European Collection of Animal Cell Cultures) were cultured in Dulbecco's modified Eagle's medium (DMEM) high glucose supplemented with 2 mM glutamine, 10% foetal bovine calf serum, and 100 U/ml penicillin and 100 g/ml streptomycin. Where appropriate, cells were treated with tumour necrosis factor-(TNF (100 ng/ml) 24 hours prior to treatment with fibrinogen, inositol phosphates and analogues were applied at the same time as fibrinogen.
Migration
A549 cells were allowed to grow to confluent monolayers in 12-well tissue culture plates and serum-starved for 24 hours. A wound was created using a p2 pipette tip. Cells were washed 3 times with fresh serum-free DMEM medium and placed in serum free DMEM for 48 hours before fibrinogen was added. Wound widths for each monolayer were measured immediately after the initial wounding and every 24 h afterwards, under microscopic vision with a graded eyepiece for 72 hours, and the distance between the confluent sheets of cells recorded. Where appropriate, cells were treated with TNF (100 ng/ml) 24 hours prior to treatment with fibrinogen. For assays analysing the effects of inositol phosphates and analogues, these were applied at the same time as fibrinogen (100 g/ml).
Proliferation
Cells were plated in 96-well tissue culture plates and serum-starved for 24 hours before fibrinogen was added for 48 hours. Proliferation was monitored by the addition of CellTiter 96AQ ueous cell proliferation reagent (Promega, Southampton, UK) and absorbance (490 nm) measured for 0-4 hours. Where appropriate, cells were treated with TNF (100 ng/ml) 24 hours prior to treatment with fibrinogen. For assays analysing the effects of inositol phosphates and analogues, these were applied at the same time as fibrinogen (100 g/ml).
Analysis of Inositol Lipid Levels
Cells were labelled with 50 Ci/ml myo-[
3 H] inositol (ARC, Cardiff, UK) in inositol-free DMEM (MP Biomedicals, Cambridge, UK) for 96 h, prior to lysis in 0.6 M HClO 4 . Inositol lipids were extracted from the HClO 4 pellet, prepared, and analysed by high performance liquid chromatography as previously described [Batty and Downes, 1994] . Peaks were ascribed by co-elution of standards in parallel runs. Inositol lipid levels were measured after 5 minutes treatment with fibrinogen. By this time, the short-lived peak of PtdInsP 3 had waned, but the sustained plateau of PtdIns(3,4)P 2 had become established. Where appropriate, cells were treated with TNF (100 ng/ml) 24 hours prior to treatment with fibrinogen; inositol phosphates and analogues were applied at the same time as fibrinogen. PtdIns(3,4)P 2 levels were normalised by dividing by the peak area for PtdIns(3,4)P 2 by PtdIns for each individual run.
Clot Formation
Thrombin-mediated fibrin formation and clot formation was performed in 96-well plates. Fibrinogen (2 mg/ml) was incubated in the presence of thrombin (0.25-1 g/ml) in a buffer comprising Tris, 50 mM (pH 7.2); NaCl, 150 mM; MgSO 4 , 1 mM; PEG (6000-8000) 0.1%. The turbidity was recorded for a period of 30 minutes as absorbance at 450 nm. Data were analysed using SoftMaxPro software (Molecular Devices, Wokingham, UK). Inositol phosphates or analogues were added prior to addition of thrombin.
RESULTS
Identification of Protein Bound to the InsP 5 Matrix
HeLa cell extracts were loaded onto the InsP 5 matrix and washed with high salt buffer. Protein samples were eluted off the matrix and analysed by HPLC MS/MS. One major peak was identified as containing peptides from fibrinogen B strand. Subsequently, intact human fibrinogen was tested, and found to bind the matrix. InsP 5 and InsP 6 readily eluted fibrinogen from the matrix at micromolar concentrations. Scyllo-InsP 5 (1 mM) was unable to elute the protein from the matrix (data not shown). BiPhP 5 was the most effective agent tested, eluting fibrinogen from the matrix at low nanomolar concentrations (Fig. 2) . These results show that inositol phosphates and analogues specifically bind TO fibrinogen.
Inositide Production
One cell surface receptor for fibrinogen is ICAM-1. Activation of ICAM-1 by fibrinogen raises the concentration of PtdIns(3,4)P 2 , an intracellular second messenger important in proliferation and migration, in a dose-dependent manner ( Fig. 3) with an EC 50 of 10 g/ml. Fibrinogen only caused an increase of PtdIns(3,4)P 2 when cells had been pretreated with the pro-inflammatory cytokine TNF . This is in keeping with the observation that expression of ICAM-1 is upregulated in A549 cells following treatment with the cytokine [Rauch et al., 2007] . InsP 5 (100 M) and InsP 6 (100 M) were able to partially reverse this increase in PtdIns(3,4)P 2 levels, whereas scyllo-InsP 5 (100 M) was without effect. BiPhP 5 (100 M) was the most effective inhibitor of PtdIns(3,4)P 2 production tested (Fig. 4) . Inositol phosphates or analogues at a concentration of 100 M had no effect in the absence of fibrinogen (data not shown).
Proliferation
We have used an MTS-based assay to study fibrinogenmediated proliferation of A549 cells. Fibrinogen was able % max response Figure 3 . Ability of fibrinogen to cause increases in PtdIns(3,4)P 2 , wound healing and proliferation. Fibrinogen was assessed for its ability to effect cellular functions in TNF -treated A549 cells. Cells were treated with fibrinogen for: 5 minutes before quenching for PtdIns(3,4)P 2 analysis (filled squares); 24-72 hours for migration assays to determine wound healing (open squares); and 48 hours for MTS assays to determine proliferation (filled circles). Data are presented mean ± se of 3-4 independent experiments.
to cause a dose-dependent increase in proliferation in cells pretreated with TNF with an EC 50 of 30 g/ml. A549 cells not treated with TNF were unaffected by fibrinogen. InsP 5 and InsP 6 were able to inhibit fibrinogenmediated proliferation, whereas scyllo-InsP 5 was without effect. BiPhP 5 was a potent inhibitor ( Figure 4 . Ability of inositol phosphates and analogues to inhibit fibrinogen-mediated increases in PtdIns(3,4)P 2 , wound healing and proliferation. The ability of InsP 6 , InsP 5 , scyllo-InsP 5 and BiPhP 5 (100 M of each) to inhibit the effects of fibrinogen (100 g/ml) on PtdIns(3,4)P 2 formation (black bars), wound healing (grey bars) and proliferation (clear bars) in TNF -treated A549 cells. Data are presented as percentage of untreated control, mean ± se of 3-6 independent experiments. * p < 0 05 compared to fibrinogen control (Dunnett's post hoc multiple comparison test). ( Fig. 5) . Inositol phosphates or analogues at a concentration of 100 M had no effect in the absence of fibrinogen (data not shown).
Wound Healing
Similar results were obtained in an in vitro wound-healing assay that mimics directional cell migration in vivo [Pinco et al., 2002] . Fibrinogen was able to effect wound healing in a dose-dependent manner, with EC 50 of 30 g/ml. A549 cells not treated with TNF were unaffected by fibrinogen. InsP 5 and InsP 6 were able to inhibit fibrinogenmediated migration, whereas scyllo-InsP 5 was without effect. BiPhP 5 was the most effective ( Fig. 5) with an EC 50 of 6 M, compared to an EC 50 of 100 M for InsP 5 (Fig. 5) . Inositol phosphates or analogues at a concentration of 100 M had no effect in the absence of fibrinogen (data not shown).
Clot Formation
We have also tested the ability of inositol phosphates and analogues to alter clot formation in an in vitro assay. Thrombin caused fibrinogen cleavage in a time-and dosedependent manner, leading to clot formation. The effects on clot formation were unaffected by all inositol phosphates and analogues tested (100 M). At higher doses many inositol phosphates were able to reduce the rate of clot formation. As this was mimicked by EDTA at equal doses, these effects were discounted as merely ion chelator properties (data not shown). Inositol phosphates or analogues at a concentration of 100 M had no effect in the absence of fibrinogen (data not shown).
DISCUSSION
Inositol phosphate analogues show some potential as anticancer drugs, once the targets have been identified and structure-activity relationships can be derived. The antiproliferative properties of higher inositol phosphates have been observed for many years [Fox and Eberl, 2002; Maffucci et al., 2005; Piccolo et al., 2004] . We now propose a novel mechanism of action for these inositol phosphates: their binding to fibrinogen.
Fibrinogen has previously been shown to drive proliferation [Gardiner and D'Souza, 1997] , migration [Rauch et al., 2007] and PI 3-K activation [Maxwell et al., 2004] of cells in 0.2-100 M (0.07-33 mg/ml). Resting levels of fibrinogen (3 mg/ml) are raised in certain cancer patients [Preston et al., 1998; Roche et al., 2003 ] making fibrinogen a risk factor in some 60% of deaths in the Western world. During blood coagulation and wound healing, fibrinogen is cleaved by thrombin and polymerises to form a fibrin matrix, providing a stroma that encourages migration and proliferation of connective tissue cells in wound healing and clot formation [Gray et al., 1993] . Fibrinogen can assemble into an extracellular matrix, in which it binds growth factors like basic fibroblast growth factor (bFGF) and VEGF with high affinity [Sahni and Francis, 2000] . The angiogenic and proliferative functions of fibrinogen have also been hijacked by many tumour cell types. Tumours can only grow to approximately 1-2 mm 3 before they require their own blood supply [Rybarczyk and Simpson-Haidaris, 2000] . By secreting fibrinogen, these cells drive cellular migration and angiogenesis. Secreted fibrinogen can form part of the extracellular matrix, enhancing the effects of certain growth factors, or acting as a proliferative agent alone [Gray et al., 1993; Rybarczyk et al., 2003] . In this respect, regulating the interaction of fibrinogen with other proteins can be a means by which we can influence many basic and complex diseases. Fibrinogen's mitogenic action can also be explained by direct binding to cell-surface receptor proteins. Fibrinogen has been shown to raise PtdIns(3,4)P 2 and PtdIns(3,4,5)P 3 levels in cells expressing IIb 3 receptors [Maxwell et al., 2004] . Binding of fibrinogen to ICAM-1 implies that it has a role in the inflammatory process, which involves cell proliferation and migration [Rauch et al., 2007] . ICAM-1 is up-regulated by proinflammatory cytokines such as TNF , interleukin-1 and interferon [Hubbard and Rothlein, 2000] . ICAM-1 has been found to be up-regulated on cell membranes in many cancers, such as gastric, pancreatic and breast cancer tissues [e.g., O'Hanlon et al., 2002] . Interestingly, inhibition of poly (ADP-ribose) polymerase downregulates NF-B and, hence ICAM-1, and appears to have anti-metastatic effects [Cuzzocrea et al., 2002] .
Fibrinogen is also important in tumour development, enhancing tumour cell migration, as well as having a direct mitogenic action itself. It can also facilitate metastasis by enhancing the sustained adherence and survival of individual tumour cell emboli in the vasculature of target organs [Roche et al., 2003] . Some of us have previously shown that the biphenyl polyphosphate BiPhP 5 is a potent ligand for the PH domain of Akt and InsP 3 5-phosphatase as well as for the Ins(1,4,5)P 3 receptor [Mills et al., 2008; Vandeput et al., 2007] . We believe that the effects seen here are not mediated by interaction of BiPhP 5 with intracellular proteins and that the effects of BiPhP 5 can be explained by its interaction with fibrinogen. By limiting the ability of fibrinogen to raise 3-phosphorylated inositol lipid levels, BiPhP 5 , along with InsP 5 and InsP 6 would reduce Akt phosphorylation without the need to enter the cytoplasm. We have found good correlation between the ability of inositol phosphates to elute fibrinogen from an InsP 5 matrix with reduction of PtdIns(3,4)P 2 formation, and inhibition of fibrinogen-mediated proliferation and migration. These studies show that BiPhP 5 has high affinity for fibrinogen and is a potent inhibitor of fibrinogen-mediated PtdIns(3,4)P 2 formation, proliferation and cell migration. Previous reports looking at downstream events (e.g., Akt phosphorylation, [Maffucci et al., 2005; Piccolo et al., 2004] ) have not measured levels of the intracellular second messengers. The reduction of 3-phosphorylated inositol lipids we have shown can explain the phenomena described in these two and related papers. This includes cell-type specificity, as not all cells express fibrinogenbinding receptors.
In addition to its role in blood clotting, fibrinogen is an important factor in cellular interactions, inflammation, cellular migration and proliferation [Standeven et al., 2005] . The targets for fibrinogen can be varied, but in A549 cells it is clear that ICAM-1 is a receptor whose expression is induced following treatment with interleukin-1, TNFor interferon- [Rothlein et al., 1988] . Binding by fibrinogen leads to activation of PI 3-K, raising levels of 3-phosphorylated inositol lipids and phosphorylation of protein targets including Akt and p38 [Rauch et al., 2007] . The physiological roles of fibrinogen have been subverted by certain cancers, making fibrinogen a target for anticancer drugs [Lu et al., 2007] .
Fibrinogen is a heparin-binding protein, heparin impeding fibrinogen binding to endothelial cells [Odrljin et al., 1996] . It is noted that other heparin-binding proteins bind higher inositol phosphates. For example, acidic and basic fibroblast growth factors (aFGF and bFGF, also referred to as FGF-1 and FGF-2, respectively) have been long known to bind InsP 6 , which blocks the proliferative effects of bFGF, but not EGF [Morrison et al., 1994] . This chelation of growth factor by inositol phosphates could, again, explain the effects of inositol phosphates on bFGF-mediated angiogenic and proliferative effects later observed by Maffucci et al. (2005) [Maffucci et al., 2005] . Many other anticancer drugs have been shown to inhibit fibrinogen binding to leukaemia cells, including cisplatin [Lu et al., 2004] , an agent found to enhance the effects of InsP 5 on apoptosis [Piccolo et al., 2004] . Like cisplatin and many frequently used anticancer drugs [Lu et al., 2004] , InsP 5 , InsP 6 and BiPhP 5 were found not to inhibit fibrin clot formation unless heroic concentrations were used (data not shown).
The bioavailability of inositol phosphates from diet has recently been questioned [Letcher et al., 2008] . A Giardia lambia InsP 6 kinase-based mass assay was used to detect levels in a variety of biological samples. No InsP 6 was detected in human plasma or urine, suggesting previous reports of micromolar concentrations may have been erroneous. Further analysis to determine whether InsP 6 in tablet form or solution [see Fox and Eberl, 2002] or BY intraperitoneal injection [Maffucci et al., 2005] raises plasma levels needs to be undertaken.
CONCLUSION
It is clear that inositol phosphates can act as anticancer drugs in vivo. Our findings that certain inositol phosphates and analogues are able to prevent formation of PtdIns(3,4)P 2 in cells treated with fibrinogen identify a new target for study. These inositol phosphates and analogues bind fibrinogen and reverse its actions in proliferation and migration assays. Our results have opened a route to the rational design of novel anti-proliferative inositol phosphate analogues utilising simple in vitro assays. Further characterisation of the inositol phosphate binding site within fibrinogen could allow computer-aided design of these compounds, the development of which has been hampered previously by the need to complete costly animal experiments.
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